בטא
רדאר קליני AI
מחקר אחד תואם לקריטריוני המסנן
תצוגת כרטיסים

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus שלב IV 638

הושלם
פרטי הניסויים הקליניים זמינים בעיקר באנגלית. רדאר קליני AI יכול לעזור! לחץ על 'הסבר את המחקר' כדי לצפות ולשוחח על מידע מהמחקר בשפה המועדפת עליך.
הניסוי הקליני NCT02688933 נערך כדי לבדוק את טיפול עבור סוכרת נעורים סוג 1. זהו מחקר שלב IV מסוג התערבותי שנמצא כעת במצב הושלם. המחקר התחיל ב-5 במאי 2016 ותוכנן לכלול 638 משתתפים. המחקר נוהל על ידי סאנופי ותאריך הסיום היה 19 ביוני 2017. מידע זה עודכן לאחרונה באתר ClinicalTrials.gov ב-28 במרץ 2022.
סיכום קצר

Primary Objective:

To demonstrate that morning injection of Toujeo (HOE901-U300) compared to Lantus provides better glycemic control evaluated by Continuous Glucose Monitoring (CGM) in adult participants with type 1 diabetes mellitus.

Secondary Objective:

To demonstrate that treatment with HOE901-U300 compared to Lantus provides:

  • Lower incidence rate of nocturnal symptomatic hypoglycemia;
  • Better glucose contr...
הצג עוד
תיאור מפורט
The maximum study duration per participant was to be of approximately 20 weeks that consisted of an up to a 4-week screening and CGM training period including a 1-2 week baseline (blinded) CGM performance (allowed for re-training), a 14-week open-label, comparative treatment period allowing for dose titration in both basal and meal-time insulin and including a 1-2 week end-of treatment blinded CGM collection with fix...הצג עוד
כותרת רשמית

A Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus

מצבים רפואיים
סוכרת נעורים סוג 1
מזהי מחקר נוספים
  • LPS14587
  • U1111-1176-0936 (מזהה אחר) (UTN)
מספר NCT
תחילת המחקר (בפועל)
2016-05-05
עדכון אחרון שפורסם
2022-03-28
סיום המחקר (מוערך)
2017-06-19
משתתפים (מתוכנן)
638
סוג המחקר
התערבותי
שלב
שלב IV
סטטוס
הושלם
מטרה ראשית
טיפול
הקצאת טיפול
אקראי
דגם מתערב
קבוצות מקבילות
עיוורון
אין (מחקר פתוח)
זרועות / התערבויות
קבוצת משתתפים/זרועהתערבות/טיפול
ניסיHOE901-U300
HOE901-U300 (Insulin glargine, 300 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting self-measured plasma glucose (SMPG) levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
HOE901-U300 (Insulin Glargine 300 U/ml)
Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast) using a pre-filled pen.
Mandated back ground therapy
Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
משווה פעילLantus
Lantus (Insulin glargine, 100 U/mL) once daily for 16 weeks on top of mealtime insulins analogs. Basal insulin doses were individually titrated (until the end of Week 14) to reach fasting SMPG levels of 80 to 100 mg/dL, while mitigating hypoglycemia.
Lantus (Insulin Glargine 100 U/ml)
Self-administered by subcutaneous (SC) injection in the morning (between waking up and breakfast using a pre-filled pen.
Mandated back ground therapy
Rapid insulin analogs: e.g., insulin glulisine, insulin lispro or insulin aspart, used by participant at least 30 days before screening. Mealtime insulin was to be continued during the study and titrated towards protocol specified postprandial glucose targets (130-180 mg/dL).
מדדי תוצאה ראשיים
מדד תוצאהתיאור המדידהטווח זמן
Percentage of Time of Mean Glucose Concentration Within the Target Range of 70-180 mg/dL as Obtained From CGM
The CGM system combined frequent interstitial glucose measurements (every 5 minutes) with ability to analyze glucose levels in real time. Adjusted least square (LS) means and standard error (SE) were obtained from a generalized linear model with identity link including post baseline CGM assessment during Week 15 (and/or Week 16).
During Week 15 and/or 16
מדדי תוצאה משניים
מדד תוצאהתיאור המדידהטווח זמן
Percentage of Participants With Documented Symptomatic Nocturnal Hypoglycemia
Documented symptomatic nocturnal hypoglycemia was defined as an event with typical symptoms of hypoglycemia accompanied by SMPG \<=70 mg/dL that occurred between 00:00 and 05:59 hours as reported on the hypoglycemia electronic case report form (eCRF).
Baseline up to Week 16
Documented Symptomatic Nocturnal Hypoglycemia Event Rate Per Participant-Year
Documented symptomatic nocturnal hypoglycemia was defined as an event with typical symptoms of hypoglycemia accompanied by SMPG \<=70 mg/dL that occurred between 00:00 and 05:59 hours as reported on the hypoglycemia eCRF.
Baseline up to Week 16
Mean Change From Baseline in Glucose Level During Last 4 Hours of CGM Data Collection Prior to the Next Day Basal Insulin Injection During Week 15 and/or Week 16
Adjusted LS means and SE were obtained from mixed model including post baseline CGM assessment during the last 4 hours prior to the next day's basal insulin injection during Week 15 (and/or Week 16).
Baseline, during Week 15 and/or Week 16
Percentage of Time Glucose Concentrations Within the Target Range of 70 to 140 mg/dL During Last 4 Hours of CGM Data Collection Prior to Next Day Basal Insulin Injection
Adjusted LS means and SE were obtained from mixed model including post baseline CGM assessment during the last 4 hours prior to the next day's basal insulin injection during Week 15 (and/or Week 16).
During Week 15 and/or Week 16
Coefficient of Variation (CV%) in Mean CGM Glucose
CV% was a measure of spread of variability relative to mean of population. For CGM glucose values over 24 hours, CV% was measure of glycemic variability across 24-hour day and calculated for each period (total, within day and between days) as ratio of standard deviation of glucose values to mean of glucose values.
During Week 15 and/or Week 16
קריטריוני זכאות

גילאים מוערכים למחקר
מבוגר, גיל שלישי
גיל מינימלי למחקר
18 Years
מגדרים מוערכים למחקר
הכל
  • Adult participants (male and female) with type 1 diabetes mellitus (T1DM).
  • Signed written informed consent.

  • Age <18 years or >70 years.
  • Fasting c-peptide ≥0.3 nmol/L as per source document or central lab test at Visit 1.
  • Glycated hemoglobin (HbA1c) ≤ 6.5 % or ≥ 10.0% via central lab test at Visit 1.
  • Participants who experienced none of episode of documented symptomatic and/or severe hypoglycemia (as per the American Diabetes Association (ADA) classification) during the past month prior to screening.
  • Participants who experienced >1 episode of severe hypoglycemia resulting in coma/seizures during the last 12 months before screening.
  • Participants received less than 1 year treatment with basal plus mealtime insulin.
  • Used any basal insulins other than long-acting insulin analogs (ie, Lantus, Toujeo, Levemir, and Tresiba) in the past 3 months before screening.
  • Required >80 U/day basal insulin analogs or not on stable dose (±20% total dose) within 30 days prior to screening.
  • Used fewer than 2 injections of rapid-acting insulin analog per day within 30 days prior to screening.
  • Used human regular insulin as mealtime insulin within 30 days prior to screening.
  • Used an insulin pump during the last 6 months before screening.
  • History of unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to required treatment (e.g., laser, surgical treatment, or injectable drugs) during the study period.
  • Pregnant or breast-feeding women or planned pregnancy during the duration of the study.
  • Use of any other investigational drug(s) within 1 month or 5 half-lives, whichever was longer prior to screening.
  • Inappropriate CGM use during screening period evidenced by failure to obtain a minimum of 4 days of usable records by the end of screening.
  • Noncompliance with self-monitored plasma glucose (SMPG) performance evidenced by failure to demonstrate at least 5 days of 5 point SMPG records by the end of screening.

The above information is not intended to contain all considerations relevant to a participants's potential participation in a clinical trial.

אין נתוני קשר.
100 מיקומי המחקר ב-2 מדינות

Arkansas

Investigational Site Number 840-151, Little Rock, Arkansas, 72205, United States

California

Investigational Site Number 840-071, Concord, California, 94520-2270, United States
Investigational Site Number 840-149, Escondido, California, 92025, United States
Investigational Site Number 840-004, Fresno, California, 93720, United States
Investigational Site Number 840-110, Greenbrae, California, 94904, United States
Investigational Site Number 840-124, La Jolla, California, 92037, United States
Investigational Site Number 840-030, La Mesa, California, 91942, United States
Investigational Site Number 840-044, Los Angeles, California, 90036, United States
Investigational Site Number 840-022, Los Angeles, California, 90057, United States
Investigational Site Number 840-129, Los Gatos, California, 95032, United States
Investigational Site Number 840-024, Northridge, California, 91325, United States
Investigational Site Number 840-069, Pomona, California, 91766, United States
Investigational Site Number 840-090, Pomona, California, 91767, United States
Investigational Site Number 840-132, Rolling Hills Estates, California, 90274, United States
Investigational Site Number 840-130, San Jose, California, 95148, United States
Investigational Site Number 840-055, San Ramon, California, 94583, United States
Investigational Site Number 840-028, Santa Barbara, California, United States
Investigational Site Number 840-063, Tarzana, California, 91356, United States
Investigational Site Number 840-138, Tustin, California, 92780-6953, United States
Investigational Site Number 840-016, Ventura, California, 93003, United States

Colorado

Investigational Site Number 840-039, Denver, Colorado, 80209, United States
Investigational Site Number 840-021, Denver, Colorado, 80246, United States
Investigational Site Number 840-070, Denver, Colorado, 80262, United States
Investigational Site Number 840-046, Englewood, Colorado, 80113, United States

Florida

Investigational Site Number 840-072, Coral Gables, Florida, 33124, United States
Investigational Site Number 840-133, Hialeah, Florida, 33016, United States
Investigational Site Number 840-137, Maitland, Florida, 32751, United States
Investigational Site Number 840-049, Miami, Florida, 33155, United States
Investigational Site Number 840-076, Miami, Florida, 33176, United States
Investigational Site Number 840-023, New Port Richey, Florida, 34652, United States
Investigational Site Number 840-053, Ocoee, Florida, 34761, United States
Investigational Site Number 840-112, Ormond Beach, Florida, 32174, United States
Investigational Site Number 840-018, Palm Harbor, Florida, 34684, United States
Investigational Site Number 840-047, Port Charlotte, Florida, 33952, United States
Investigational Site Number 840-114, Tampa, Florida, 33612, United States
Investigational Site Number 840-036, West Palm Beach, Florida, 33401, United States

Georgia

Investigational Site Number 840-001, Atlanta, Georgia, 30318, United States
Investigational Site Number 840-064, Columbus, Georgia, 31904, United States
Investigational Site Number 840-012, Lawrenceville, Georgia, 30046, United States
Investigational Site Number 840-008, Roswell, Georgia, 30076, United States
Investigational Site Number 840-014, Stockbridge, Georgia, 30281, United States

Idaho

Investigational Site Number 840-060, Idaho Falls, Idaho, 83404, United States

Illinois

Investigational Site Number 840-125, Arlington Heights, Illinois, 60005, United States
Investigational Site Number 840-011, Chicago, Illinois, 60612, United States
Investigational Site Number 840-134, Crystal Lake, Illinois, 60012, United States

Iowa

Investigational Site Number 840-002, West Des Moines, Iowa, 50265, United States

Kansas

Investigational Site Number 840-073, Wichita, Kansas, 67226, United States

Kentucky

Investigational Site Number 840-062, Covington, Kentucky, 41011, United States
Investigational Site Number 840-042, Lexington, Kentucky, 40503, United States

Louisiana

Investigational Site Number 840-009, Metairie, Louisiana, 70006, United States
Investigational Site Number 840-032, New Orleans, Louisiana, 70115, United States

Maryland

Investigational Site Number 840-054, Hyattsville, Maryland, 20782, United States
Investigational Site Number 840-006, Rockville, Maryland, 20852, United States

Massachusetts

Investigational Site Number 840-157, Framingham, Massachusetts, 01702, United States
Investigational Site Number 840-122, Waltham, Massachusetts, 02453, United States

Michigan

Investigational Site Number 840-037, Flint, Michigan, 48532, United States

Montana

Investigational Site Number 840-067, Billings, Montana, 59101, United States

Nebraska

Investigational Site Number 840-094, Lincoln, Nebraska, 68526, United States
Investigational Site Number 840-033, Omaha, Nebraska, 68114, United States
Investigational Site Number 840-142, Omaha, Nebraska, 68124, United States

Nevada

Investigational Site Number 840-040, Henderson, Nevada, 89052, United States
Investigational Site Number 840-017, Las Vegas, Nevada, 89148, United States

New York

Investigational Site Number 840-102, New York, New York, 10001, United States
Investigational Site Number 840-108, New York, New York, 10029, United States
Investigational Site Number 840-109, Staten Island, New York, 10301-3914, United States

North Carolina

Investigational Site Number 840-045, Greenville, North Carolina, 27834, United States
Investigational Site Number 840-010, Morehead City, North Carolina, 28557, United States
Investigational Site Number 840-080, Morehead City, North Carolina, 28557, United States

North Dakota

Investigational Site Number 840-051, Fargo, North Dakota, 58103, United States

Ohio

Investigational Site Number 840-123, Columbus, Ohio, 43203, United States
Investigational Site Number 840-104, Mentor, Ohio, 44060, United States

Oklahoma

Investigational Site Number 840-079, Norman, Oklahoma, 73069, United States

Oregon

Investigational Site Number 840-162, Bend, Oregon, 97702, United States
Investigational Site Number 840-096, Portland, Oregon, 97210, United States

Tennessee

Investigational Site Number 840-058, Chattanooga, Tennessee, 37411, United States

Texas

Investigational Site Number 840-003, Dallas, Texas, 75230, United States
Investigational Site Number 840-019, Dallas, Texas, 75231, United States
Investigational Site Number 840-075, Dallas, Texas, 75235, United States
Investigational Site Number 840-005, Dallas, Texas, 75246, United States
Investigational Site Number 840-013, Dallas, Texas, 75246, United States
Investigational Site Number 840-153, El Paso, Texas, 79925, United States
Investigational Site Number 840-026, Fort Worth, Texas, 76132, United States
Investigational Site Number 840-081, Houston, Texas, 77024, United States
Investigational Site Number 840-160, Houston, Texas, 77043, United States
Investigational Site Number 840-156, Houston, Texas, 77079, United States
Investigational Site Number 840-152, Houston, Texas, 77089, United States
Investigational Site Number 840-031, Houston, Texas, 77095, United States
Investigational Site Number 840-140, Lufkin, Texas, 75904, United States
Investigational Site Number 840-029, Mesquite, Texas, 75149, United States
Investigational Site Number 840-048, North Richland Hills, Texas, 76180, United States
Investigational Site Number 840-150, Pearland, Texas, 77584, United States

Utah

Investigational Site Number 840-083, Murray, Utah, 84123, United States
Investigational Site Number 840-101, Ogden, Utah, 84405, United States
Investigational Site Number 840-097, Salt Lake City, Utah, 84102, United States

Vermont

Investigational Site Number 840-143, Bennington, Vermont, 05201, United States
Investigational Site Number 840-056, Burlington, Vermont, 05405, United States

Washington

Investigational Site Number 840-015, Renton, Washington, 98055, United States
Investigational Site Number 840-074, Spokane, Washington, 99207, United States

West Virginia

Investigational Site Number 840-139, Bridgeport, West Virginia, 26330, United States
Investigational Site Number 840-111, Manatí, 00674, Puerto Rico